The Latest research study released by Absolute Markets Insights Cilnidipine Market with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth.In terms of revenue, the global cilnidipine market was valued at US$ 9802.50 Mn in 2022 and is expected to reach US$ 48552.98 Mn by 2030, growing at a CAGR of 19.52% over the forecast period (2022 – 2030). Some of the Major Companies covered in this Research are: Abbott, Ajanta Pharma Ltd, Alembic Pharmaceuticals Ltd, Alkem Laboratories Ltd, Eris Lifesciences Ltd, Fuji Viscera Pharmaceutical Company and Ajinomoto Intas Pharmaceuticals Ltd, J B Chemicals and Pharmaceuticals Ltd, Lupin Ltd, Macleods Pharmaceuticals Pvt Ltd, Mankind Pharma Ltd, Medley Pharmaceuticals, Micro Labs Ltd, Niksan Pharmaceutical, Sun Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd, Trumac Healthcare, ZydusCadila, amongst others.
Request a report sample to gain comprehensive insights @ https://www.absolutemarketsinsights.com/request_sample.php?id=803
Global Cilnidipine Market:
- High Blood Pressure (Hypertension)
- Prevent Heart Attacks and Strokes
- Prevent Angina (Heart-Related Chest Pain)
- Decrease Protein Leakage from the Kidney in Patients who Have Diabetes
- 10mg Tablet
- Combination Doses
Purchase the latest in-depth Cilnidipine Market report: https://www.absolutemarketsinsights.com/checkout?id=803
The prevalence of illnesses as a result of urbanization, and the rising competition in workplace, is a global phenomena. Several countries reported a rise in cases of hypertension, and heart related illness in the last 20 years, predominantly due to the changes in lifestyle amongst individuals. Higher competition in the workplace which is leading to a deterioration of health condition, and increased pressure amongst students is a serious concern amongst government health bodies, especially in the APAC region. The treatment of hypertension is made possible by the use of Cilnidipine, which is essentially a calcium channel blocker. It is accompanied with both L-type and N-type calcium channel blocking capabilities. The drug was developed by Fuji Viscera Pharmaceutical Company, and Ajinomoto, which are companies based in Japan. Cilnidipine was approved for use as a medicine in 1995, after it was patented in 1984. Apart from hypertension, Cilnidipine has also been proven to reduce blood pressure, decrease protein leakage from kidney, angina, amongst others.
Cilnidipine helps in the dilation of arterioles and venules, thereby reducing the pressure in the capillary bed due to its blocking action at both N-type and L-type calcium channels. Cilnidipine presents a rapid absorption, and the concentration peak is generally observed after two hours. The distribution is higher in the kidney, as well as the liver. But, Cilnidipine has been reported to present low bioavailability, which is observed to be approximately 13%. The drug is metabolised quickly by both the liver and the kidney. In the liver, it is metabolized at a faster pace due to the presence of microsomes through the process of hydrogenation. Cilnidipine containing drugs are also available at economical rates, especially in countries like India and China. In India, for instance, Cilacar, a drug that contains cilnidipine, which is manufactured by J B Chemicals and Pharmaceuticals Ltd, is available for US$ 0.12 per tablet. The global cilnidipine market is seeing considerable growth due to the rising demand for efficient management of hypertension, especially amongst the geriatric population.
The use of cilnidipine in patients is associated with several side effects such as feet swelling, tiredness, headache, nausea, depression, stomach pain and male sexual dysfunction, amongst others. In rare cases, abnormal functioning of the liver is also observed. The drug is not advised for patients who have suffered a recent heart attack, have low blood pressure due to various heart conditions, etc. Increasing efficiency of cilnidipine drugs, and management of the aforementioned side effects with the help of technology will lead to the further adoption of cilnidipine drugs, thereby leading to the growth of the global cilnidipine market.
The COVID-19 pandemic has taken the world by storms. The mutation of coronavirus is presenting additional challenges to government bodies, and lockdown measures are being mulled over in several countries. Businesses have also taken a serious hit due to the COVID-19 pandemic. Healthcare bodies are working overtime to ensure safe treatment of individuals who have been affected by the coronavirus. Home-based treatment of non-serious illnesses has seen a significant spike in the last 12 months, as individuals are increasingly choosing to avoid hospitals due to the threat of COVID-19 spread. Loss in revenue has resulted in massive lay-offs and salary cut by various companies, and this has lead to a rise in stress in numerous individuals. The ability of the cilnidipine drug in managing hypertension is expected to drive its adoption amongst individuals who have fallen victim to hypertension and stress caused due to both social and professional anxiety during the pandemic. Therefore, the COVID-19 pandemic is expected to have a positive impact on the global cilnidipine market in the coming years.
Cilnidipine Market Report Highlights:
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.
Read Detailed Index of full Research Study @ https://www.absolutemarketsinsights.com/reports/Cilnidipine-Market-2021---2029-803
Browse more trending reports by Absolute Markets Insights:
Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.
Contact Name: Shreyas Tanna
Company: Absolute Markets Insights
Email Id: [email protected]
Phone: IN +91-7400-24-24-24, US +1-510-420-1213